Definium Therapeutics (DFTX) Other Non-Current Liabilities (2021 - 2026)
Definium Therapeutics' (DFTX) quarterly Other Non-Current Liabilities came in at $559000.0 in Q1 2026, down 96.87% year-on-year from $17.8 million in Q1 2025, and up 12.7% on a QoQ basis from $496000.0 in Q4 2025.
Definium Therapeutics (DFTX) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 6 years of Other Non-Current Liabilities data on file, last reported at $559000.0 in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities fell 96.87% year-over-year to $559000.0 in Q1 2026; TTM through Mar 2026 was $559000.0, a 96.87% decrease from a year earlier, with the FY2025 full-year figure at $496000.0, down 98.03% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $559000.0, up from $496000.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for DFTX reached as high as $25.2 million in Q4 2024 and fell as low as $15000.0 in Q1 2024.
- Historically, Other Non-Current Liabilities has averaged $4.5 million across 5 years, with a median of $966000.0 in 2024.
- Across the five-year window, Other Non-Current Liabilities plunged 98.62% in 2024 and surged 118866.67% in 2025, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $1.2 million in 2022, then sank by 97.3% to $32000.0 in 2023, then surged by 78518.75% to $25.2 million in 2024, then tumbled by 98.03% to $496000.0 in 2025, then increased by 12.7% to $559000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $559000.0 in Q1 2026, $496000.0 in Q4 2025, and $519000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Definium Therapeutics | 4.47 Bn | 4.47 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 559,000.00 |
| Dec 31, 2025 | 496,000.00 |
| Sep 30, 2025 | 519,000.00 |
| Jun 30, 2025 | 543,000.00 |
| Mar 31, 2025 | 17.85 Mn |
| Dec 31, 2024 | 25.16 Mn |
| Sep 30, 2024 | 22.32 Mn |
| Jun 30, 2024 | 966,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Sep 30, 2023 | 349,000.00 |
| Jun 30, 2023 | 992,000.00 |
| Mar 31, 2023 | 1.09 Mn |
| Dec 31, 2022 | 1.18 Mn |
| Sep 30, 2022 | 1.28 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Mar 31, 2022 | 490,000.00 |
| Dec 31, 2021 | 1.93 Mn |